Hainan Honz Pharmaceutical Co (300086) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hainan Honz Pharmaceutical Co (300086) has a cash flow conversion efficiency ratio of -0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-9.17 Million ≈ $-1.34 Million USD) by net assets (CN¥1.07 Billion ≈ $157.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Hainan Honz Pharmaceutical Co's balance sheet to measure how much of total assets are equity-financed.
Hainan Honz Pharmaceutical Co - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Hainan Honz Pharmaceutical Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Hainan Honz Pharmaceutical Co cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Hainan Honz Pharmaceutical Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hainan Honz Pharmaceutical Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
C&C Group PLC
F:GCC
|
0.023x |
|
Anhui Wantong Technology Co Ltd
SHE:002331
|
-0.065x |
|
Robostar Co.Ltd
KQ:090360
|
-0.018x |
|
Hemisphere Properties India Limited
NSE:HEMIPROP
|
0.000x |
|
Taiwan Paiho Ltd
TW:9938
|
0.049x |
|
Kaveri Seed Company Limited
NSE:KSCL
|
-0.083x |
|
Cerus Corporation
NASDAQ:CERS
|
-0.045x |
|
Dongrui Food Group Co Ltd
SHE:001201
|
0.004x |
Annual Cash Flow Conversion Efficiency for Hainan Honz Pharmaceutical Co (2007–2025)
The table below shows the annual cash flow conversion efficiency of Hainan Honz Pharmaceutical Co from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Hainan Honz Pharmaceutical Co market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥921.22 Million ≈ $134.80 Million |
CN¥121.24 Million ≈ $17.74 Million |
0.132x | +114.62% |
| 2024-12-31 | CN¥1.17 Billion ≈ $170.52 Million |
CN¥71.46 Million ≈ $10.46 Million |
0.061x | +19.53% |
| 2023-12-31 | CN¥1.38 Billion ≈ $201.65 Million |
CN¥70.69 Million ≈ $10.34 Million |
0.051x | +137.15% |
| 2022-12-31 | CN¥1.36 Billion ≈ $198.35 Million |
CN¥29.32 Million ≈ $4.29 Million |
0.022x | +196.65% |
| 2021-12-31 | CN¥1.55 Billion ≈ $227.35 Million |
CN¥11.33 Million ≈ $1.66 Million |
0.007x | +169.76% |
| 2020-12-31 | CN¥1.60 Billion ≈ $234.39 Million |
CN¥-16.74 Million ≈ $-2.45 Million |
-0.010x | -137.16% |
| 2019-12-31 | CN¥1.60 Billion ≈ $234.40 Million |
CN¥45.06 Million ≈ $6.59 Million |
0.028x | -70.50% |
| 2018-12-31 | CN¥1.65 Billion ≈ $241.97 Million |
CN¥157.66 Million ≈ $23.07 Million |
0.095x | +907.72% |
| 2017-12-31 | CN¥1.92 Billion ≈ $281.05 Million |
CN¥18.17 Million ≈ $2.66 Million |
0.009x | -80.51% |
| 2016-12-31 | CN¥1.87 Billion ≈ $274.03 Million |
CN¥90.88 Million ≈ $13.30 Million |
0.049x | +14.15% |
| 2015-12-31 | CN¥1.84 Billion ≈ $269.49 Million |
CN¥78.30 Million ≈ $11.46 Million |
0.043x | +3.78% |
| 2014-12-31 | CN¥1.80 Billion ≈ $264.07 Million |
CN¥73.93 Million ≈ $10.82 Million |
0.041x | -6.05% |
| 2013-12-31 | CN¥1.81 Billion ≈ $264.88 Million |
CN¥78.93 Million ≈ $11.55 Million |
0.044x | -25.37% |
| 2012-12-31 | CN¥1.87 Billion ≈ $274.16 Million |
CN¥109.46 Million ≈ $16.02 Million |
0.058x | +207.30% |
| 2011-12-31 | CN¥1.85 Billion ≈ $271.29 Million |
CN¥-100.94 Million ≈ $-14.77 Million |
-0.054x | -224.62% |
| 2010-12-31 | CN¥1.83 Billion ≈ $267.58 Million |
CN¥79.89 Million ≈ $11.69 Million |
0.044x | -88.77% |
| 2009-12-31 | CN¥240.49 Million ≈ $35.19 Million |
CN¥93.58 Million ≈ $13.69 Million |
0.389x | -6.52% |
| 2008-12-31 | CN¥150.41 Million ≈ $22.01 Million |
CN¥62.61 Million ≈ $9.16 Million |
0.416x | +57.69% |
| 2007-12-31 | CN¥115.89 Million ≈ $16.96 Million |
CN¥30.59 Million ≈ $4.48 Million |
0.264x | -- |
About Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of pediatric medicines in China. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, relieving cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine; and medical, disposable, and protective face ma… Read more